Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19504938 | 0.82 | EPHX1 (0.39) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL22413862 | 0.80 | — | — | |
| SCHEMBL19663790 | 0.76 | CRHBP (0.37) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL15716234 | 0.75 | CRHBP (0.33) | CRHBPCRHR2 | |
| SCHEMBL23277994 | 0.70 | EPHX1 (0.33) | — | |
| SCHEMBL23641693 | 0.70 | GRIN2D (0.36) | — | |
| SCHEMBL10188213 | 0.70 | EPHX1 (0.33) | — | |
| SCHEMBL23277844 | 0.70 | EPHX1 (0.33) | — | |
| SCHEMBL23219577 | 0.69 | GRIN2D (0.35) | — | |
| SCHEMBL24091187 | 0.69 | GRIN2D (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2019-03-07 | — | — | US | disclosed |
| US-9981922-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981922-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CRHBP 2815/4885CRHR2 4754/4885ALDH1A1 1575/4885 |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | CRHBP 2815/4885CRHR2 4754/4885ALDH1A1 1575/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CRHBP 4298/4885CRHR2 3841/4885ALDH1A1 1320/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CRHBP 4298/4885CRHR2 3841/4885ALDH1A1 1320/4885 |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | CRHBP 3651/4885CRHR2 4602/4885ALDH1A1 734/4885 |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | CRHBP 2815/4885CRHR2 4754/4885ALDH1A1 1575/4885 |
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM2A | CRHBP 3352/4885CRHR2 4547/4885ALDH1A1 1778/4885 |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CRHBP 2815/4885CRHR2 4754/4885ALDH1A1 1575/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | CRHBP 3651/4885CRHR2 4602/4885ALDH1A1 734/4885 |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CRHBP 2815/4885CRHR2 4754/4885ALDH1A1 1575/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | CRHBP 2902/4885CRHR2 4752/4885ALDH1A1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.